OVAS Stock News 7.21 05/13/2014 17:22:41 Ovascience Inc (OVA

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ovascience Inc (OVAS) 7.21 $OVAS

OvaScience Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:01AM CDT
OvaScience(SM), (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported first quarter 2014 financial results, and highlighted recent accomplishments.

OvaScience to Present at the 39th Annual Deutsche Bank Health Care Conference
Business Wire - Thu May 01, 7:30AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Michelle Dipp, M.D., Ph.D., Chief Executive of OvaScience, will present at the 39th Annual Deutsche Bank Securities Health Care Conference on Thursday, May 8, at 8:00am EDT in the InterContinental Boston Hotel.

OvaScience Co-Founder David Sinclair, Ph.D., Selected by TIME as one of the 100 Most Influential People in The World
Business Wire - Thu Apr 24, 7:03AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced that the Company's scientific Co-Founder, David Sinclair, Ph.D., has been selected for the 2014 TIME 100, TIME's annual list of the 100 most influential people in the world. Dr. Sinclair's extensive research on aging and the key role of mitochondria (the energy source for all cells) contributed to OvaScience's foundational egg precursor cell (EggPC(SM)) technology platform. The Company expects to launch its first fertility product, AUGMENT(SM), in international in vitro fertilization (IVF) clinics in 2014. AUGMENT is designed to improve egg quality and the success of IVF by enhancing mitochondrial function.

How OvaScience (OVAS) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:42AM CDT
OvaScience has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front

OvaScience Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
Business Wire - Tue Mar 18, 7:31AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 518,630 shares of common stock at the public offering price of $10.00 per share. As a result, total gross proceeds to OvaScience from this offering are $55.2 million before deducting the underwriting discounts, commissions and estimated expenses.

OvaScience to Present at the 26th Annual ROTH Conference
Business Wire - Thu Mar 06, 7:31AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience will present at the 26th Annual ROTH Conference on Tuesday, March 11 at 12:30pm Pacific Standard Time. The conference will take place at the Ritz-Carlton in Laguna Niguel, California.

OvaScience (OVAS) in Focus: Stock Tanks 9.5% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:48AM CST
OvaScience fell 9.5% last trading session, reversing the recent trend

Nasdaq stocks posting largest volume increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

OvaScience Prices $50 Million Public Offering of Common Stock
Business Wire - Tue Mar 04, 7:35AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced the pricing of $10.00 per share for its previously announced underwritten public offering of 5,000,000 shares of its common stock. Gross proceeds to OvaScience from this offering are expected to be approximately $50 million, and the Company intends to use the net proceeds to fund OvaPrime(SM) preclinical studies and the anticipated 2015 international launch, establish an international subsidiary, expand the AUGMENT(SM) international launch, and for other general corporate purposes.

OvaScience Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:05PM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today it has commenced an underwritten public offering of shares of its common stock. OvaScience intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering will be sold by OvaScience.

OvaScience Reports Fourth Quarter and Year End 2013 Financial Results
Business Wire - Thu Feb 27, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported fourth quarter and year end 2013 financial results, and highlighted recent accomplishments.

OvaScience (OVAS) in Focus: Stock Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
OvaScience, Inc. (OVAS) was a big mover last session, as its shares rose nearly 6% on the day.

2 Health Care Stocks Under $10 to Trade
at The Street - Thu Feb 20, 5:00AM CST
These health care stocks under $10 were trading higher on Wednesday. Here's how to trade them now.

OvaScience Issued Two U.S. Patents Covering AUGMENT(SM) Fertility Treatment
Business Wire - Wed Feb 12, 7:30AM CST
OvaScience(SM) (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced the issuance of two United States patents covering its AUGMENT(SM) fertility treatment. AUGMENT is based on the Company's egg precursor cell (EggPC(SM)) technology and is being developed to improve egg quality and the success of in vitro fertilization (IVF). AUGMENT will be available in international IVF clinics this year.

OvaScience Appoints Fertility Pioneer Jamie Grifo M.D., Ph.D., to Clinical Advisory Board
Business Wire - Tue Feb 04, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, announced today the appointment of Jamie Grifo, M.D., Ph.D., of the New York University (NYU) Fertility Center and the Division of Reproductive Endocrinology at the NYU School of Medicine, to its Clinical Advisory Board.

OvaScience to Present at Upcoming Conferences
Business Wire - Mon Feb 03, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that the Company's management team will present at two upcoming conferences in February. The conference and OvaScience presentation details are as follows:

OvaScience (OVAS) in Focus: Stock Tumbles 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:34AM CST
OvaScience stock tumbles 8% yesterday, continuing the recent downtrend

OvaScience Provides Update on Pipeline Advancements and Commercial Plans; New Potential Fertility Treatment OvaPrime(SM) to Launch in 2015
Business Wire - Mon Jan 13, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg precursor cell (EggPC(SM)) technology platform. OvaScience expects to commercialize AUGMENT(SM) in international in vitro fertilization (IVF) clinics in 2014 and to launch its newest potential fertility treatment, OvaPrime(SM), in 2015.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 278

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 81

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 69

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 98

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 99

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 276

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 139

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading

Top 5 Most Recently Viewed Articles

PHX Minerals Set to Release Full-Year 2024 Financial Results

Updated Category News Views 176

PHX Minerals Reveals Upcoming Financial Results Announcement PHX MINERALS INC., commonly known as PHX, is preparing to share its financial results for the year that concluded on December 31, 2024. This announcement is eagerly awaited by investors and stakeholders, marking a significant moment in understanding the company’s financial health and future outlook. Details of...

Continue Reading
Baird Optimistic on First Industrial Realty Trust Growth Ahead

Updated Category News Views 183

Baird's Positive Outlook for First Industrial Realty Trust Baird has reaffirmed its positive stance on First Industrial Realty Trust (NYSE: FR), maintaining an Outperform rating alongside a $61.00 price target. The firm's analysis indicates that the company's core portfolio is projected to deliver a stable 6% annual growth, signaling strong performance prospects for...

Continue Reading
Aprea Therapeutics Secures $3.1 Million Investment for Growth

Updated Category News Views 151

Aprea Therapeutics Secures $3.1 Million Investment Aprea Therapeutics, Inc. (Nasdaq: APRE), a forward-thinking clinical-stage biopharmaceutical company, has announced a notable private placement aimed at enhancing its development of innovative cancer treatments. This financing comes from a blend of new and existing investors, reflecting confidence in the company’s...

Continue Reading
Silal and SVG Forge New Paths in Sustainable Agriculture

Updated Category News Views 174

Silal and SVG Forge New Paths in Sustainable Agriculture In a significant development for the agricultural sector, Silal, a leading agri-food and technology company, and Shouguang Colorful Manor Modern Agriculture Co., Ltd (SVG) have entered a joint venture that stands to revolutionize sustainable agriculture practices. This landmark agreement was witnessed by eminent...

Continue Reading